DE102015008823A1 - Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol - Google Patents

Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol Download PDF

Info

Publication number
DE102015008823A1
DE102015008823A1 DE102015008823.8A DE102015008823A DE102015008823A1 DE 102015008823 A1 DE102015008823 A1 DE 102015008823A1 DE 102015008823 A DE102015008823 A DE 102015008823A DE 102015008823 A1 DE102015008823 A1 DE 102015008823A1
Authority
DE
Germany
Prior art keywords
curcumin
aerosol
powder
performance evaporator
mesh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102015008823.8A
Other languages
German (de)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102015008823.8A priority Critical patent/DE102015008823A1/en
Publication of DE102015008823A1 publication Critical patent/DE102015008823A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/36—General characteristics of the apparatus related to heating or cooling
    • A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Verfahrenspatent zur Verwendung des Verfahrens und der Vorrichtungen zum Verdampfen von Curcumin-Pulver mit einem Hochleistungs-Verdampfer zwecks Erzeugen eines inhalierbaren Curcumin-Aerosols. Der Hochleistungs-Verdampfer muss eine Temperatur von mindestens 591,4°C/1096,5°F erreichen. Das erzeugte Curcumin-Aerosol wird über einen Glaskolben mit Mundstück, über eine Wasserpfeife oder aus einem Ventil-Ballon in den es zwischengeschpeichert wurde, eingeatmet.A process patent for using the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol. The high performance evaporator must reach a temperature of at least 591.4 ° C / 1096.5 ° F. The generated curcumin aerosol is inhaled via a glass flask with mouthpiece, a water pipe or a valve balloon in which it was temporarily stored.

Description

Curcumin, ein Gelbwurzelextrakt, ist die wichtigste bioaktive Komponente von Curcuma Longa L. Das Curcumin-Extrakt (Jupiter Leys) besteht aus 82% curcumin, 16% demethoxycurcumin (DMC), and 2% bis-demethoxycurcumin (BDMC) und wird im Folgenden als Curcumin oder Curcumin-Pulver bezeichnet.Curcumin, a turmeric extract, is the major bioactive component of Curcuma Longa L. The curcumin extract (Jupiter Leys) consists of 82% curcumin, 16% demethoxycurcumin (DMC), and 2% bis-demethoxycurcumin (BDMC) and is referred to below Curcumin or curcumin powder.

Der Siedepunkt des Curcumin-Pulvers liegt bei 591,4°C/1096,5°F.The boiling point of the curcumin powder is 591.4 ° C / 1096.5 ° F.

Curcuma ist ein weit verbreitetes natürliches Nahrungsmittel in der indischen und chinesischen Ernährung. Curcuma ist in Curry-Pulver und im Senf (Lebensmittelfarbstoff E100) enthalten.Curcuma is a widely used natural food in the Indian and Chinese diets. Curcuma is contained in curry powder and mustard (food coloring E100).

Curcuma wird seit Jahrtausenden auch als Heilmittel in der traditionellen indischen und chinesischen Medizin verwendet.Curcuma has been used for millennia as a remedy in traditional Indian and Chinese medicine.

Curcumin ist in den letzten Jahren in den Fokus der Schulmedizin geraten. In mehr als 4500 globalen klinischen Studien haben sich die Vorteile der Behandlung mit Curcumin gezeigt. Es wurden klinische Studien u. a. auf folgenden Gebieten durchgeführt: Krebs, Alzheimer, Parkinson, Morbus Crohn, Arthritis, Immunschwäche, Vasodilatation, Diabetes. Nachweislich wirkt Curcumin auch präventiv: neuroprotektiv, entzündungshemmend, LDL-senkend.Curcumin has come in the past few years in the focus of conventional medicine. The benefits of curcumin treatment have been demonstrated in more than 4,500 global clinical trials. There have been clinical studies u. a. Cancer, Alzheimer's, Parkinson's, Crohn's disease, arthritis, immunodeficiency, vasodilation, diabetes. Curcumin also has a preventive effect: neuroprotective, anti-inflammatory, LDL-lowering.

Die einzelnen Studien zur Bioverfügbarkeit von Curcumin sind dabei nur bedingt vergleichbar, da es teilweise erhebliche Unterschiede in der Höhe der Curcumin-Dosen gibtThe individual studies on the bioavailability of curcumin are only partially comparable, as there are sometimes considerable differences in the amount of curcumin doses

Die Studienergebnisse zeigen das Curcumin ein effizienter Wirkstoff ist. Obwohl die Daten der Studien die positive Wirkung von Curcumin im Zusammenhang mit verschiedenen Krankheiten zeigen, behindert seine geringe systemische Bioverfügbarkeit seine klinische Entwicklung und Einsatzbarkeit.The study results show that curcumin is an effective active ingredient. Although data from the studies show the beneficial effects of curcumin on various diseases, its low systemic bioavailability hampers its clinical development and usability.

Das Potenzial gesundheitlicher Vorteile von Curcumin ist durch seine schlechte Löslichkeit, geringe Absorption aus dem Darm, schnellen Stoffwechsel und schnelle systemische Eliminierung begrenzt.The potential health benefits of curcumin is limited by its poor solubility, low intestinal absorption, rapid metabolism and rapid systemic elimination.

Die maximale Plasmakonzentrationen Curcumin beim Menschen, auch nach Einnahme von Dosen von 10 oder 12 g Curcumin, bleiben im Bereich von niedrigen Nano-Werten.The maximum plasma curcumin concentrations in humans, even after doses of 10 or 12 g curcumin, remain in the range of low nano values.

Forscher haben eine Anzahl von unterschiedlichen Strategien, wie die Hemmung des Curcumin-Stoffwechsels mit Adjuvantien, neuartige feste und flüssige orale Trägersysteme, Micellation und Micronization, erstellt und haben sie auf ihr Potenzial zur Optimierung der biologischen Verfügbarkeit von Curcumin untersucht. Die veröffentlichen Studien zeigen eine Erhöhung der Bioverfügbarkeit (basierend auf der Fläche unter der Plasma-Konzentration-Zeit-Kurve (AUC)) im Vergleich zum nativen Curcumin.Researchers have developed a number of different strategies, such as the inhibition of curcumin metabolism with adjuvants, novel solid and liquid oral delivery systems, micellization and micronization, and have investigated their potential for optimizing the bioavailability of curcumin. The published studies show an increase in bioavailability (based on the area under the plasma concentration-time curve (AUC)) compared to native curcumin.

Bis zu diesem Zeitpunkt habe ich nur eine Studie über das Inhalieren von Curcumin-Dampf gefunden:
Inhalable Curcumin: Offering the Potential for Translation to Imaging and Treatment of Alzheimer's Disease Authors: McClure, Richard | Yanagisawa, Daijiro | Stec, Donald | Abdollahian, Dave | Koktysh, Dmitry | Xhillari, Dritan | Jaeger, Rudolph | Stanwood, Gregg | Chekmenev, Eduard | Tooyama, Ikuo | Gore, John C. | Pham, Wellington By this time, I have only found one study on inhaling curcumin vapor:
Inhalable Curcumin: Offering the Potential for Translation and Treatment of Alzheimer's Disease Authors: McClure, Richard | Yanagisawa, Daijiro | Stec, Donald | Abdollahian, Dave | Koktysh, Dmitry | Xhillari, Dritan | Jaeger, Rudolph | Stanwood, Gregg | Chekmenev, Eduard | Tooyama, Ikuo | Gore, John C. | Pham, Wellington

Abstract:Abstract:

  • Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimers disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blond-brain barrier. Presently, curcumin can be applied only to animal models, as the formulation needed for iv injection renders it unfit for human use. Here, we describe a novel technique to aerosolize a curcumin derivative, FMeC1, and facilitate its safe delivery to the brain. Aside from the translational applicability of this approach, a study in the 5XFAD mouse model suggested that inhalation exposure to an aerosolized FMeC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms that following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimer's disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blond-brain barrier. Presently, curcumin can be applied to animal models, as the formulation is needed for intravenous injection. Here, we describe a novel technique to aerosolize a curcumin derivative, FMec1, and facilitate its safe delivery to the brain. FMEC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms the following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.
  • DOI: 10.3233/JAD-140798 Journal: Journal of Alzheimer's Disease, vol. 44, no. 1, 2015 Pages 283–295DOI: 10.3233 / JAD-140798 Journal: Journal of Alzheimer's Disease, vol. 44, no. 1, 2015 Pages 283-295

Die wichtigsten Ergebnisse der o. g. Studie sind der Nachweis, dass Curcumin die Blut-Hirn-Schranke überwinden kann und Amyloid-Plaques binden kann. FMeC1 ist eine giftige Curcumin-Fluor-Verbindung die nur zum Nachweis des Curcumin im Hirn diente. Die o. g. Studie kann als Anregung und Motivation für die vorliegende Erfindung betrachtet werden.The most important results of the o. G. Study evidence that curcumin can cross the blood-brain barrier and bind amyloid plaques. FMeC1 is a toxic curcumin-fluorine compound used only to detect curcumin in the brain. The o. G. Study may be considered as a suggestion and motivation for the present invention.

In der Schulmedizin findet Curcumin insbesondere in Verbindung mit Neurogenese (Alzheimer) und Karzinogenese (Krebs) eine besondere Aufmerksamkeit. Um diese primär altersbedingten Volkskrankheiten präventiv und kurativ behandeln zu können, ist die Optimierung der Absorption bzw. der Bioverfügbarkeit erforderlich. Die Aufgabe der vorliegenden Erfindung ist es demnach ein Verfahren und eine darauf basierende Vorrichtung zur Erhöhung der Absorption bzw. der Bioverfügbarkeit von Curcumin bereit zu stellen.In conventional medicine curcumin finds particular attention in connection with neurogenesis (Alzheimer's disease) and carcinogenesis (cancer). In order to be able to treat these primarily age-related widespread diseases preventively and curatively, it is necessary to optimize absorption or bioavailability. The object of the present invention is therefore a method and a device based thereon for increasing the Absorption or bioavailability of curcumin.

Dieses wird primär durch die Inhalation von Curcumin-Dampf, der durch einen Hochleistungs-Verdampfer erzeugt wird, erreicht. Der Hochleistungs-Verdampfer, mit deutlich erhöhtem Wirkungsgrad gegenüber den üblichen Verdampfer, verdampft das Curcumin-Pulver, dessen Siedepunkt bei 591,4°C/1096,5°F liegt.This is achieved primarily by the inhalation of curcumin vapor generated by a high performance evaporator. The high performance evaporator, with significantly increased efficiency over conventional evaporators, vaporizes the curcumin powder whose boiling point is 591.4 ° C / 1096.5 ° F.

Auf dem Markt gibt es eine überschaubare Anzahl von Verdampfer:

  • • Verdampfer, Spule mit Docht (coil with wick). der elektronischen Zigaretten für e-Liquids und
  • • Vaporizer für Pflanzenmaterialien (Aromen und Düfte), Flüssigkeiten (Aromen), Ölen und Wachse
On the market there are a manageable number of evaporators:
  • • Evaporator, coil with wick (coil with wick). of electronic cigarettes for e-liquids and
  • • Vaporizer for plant materials (aromas and fragrances), liquids (aromas), oils and waxes

Diese Verdampfer können nur Materialien mit dem Siedepunkt < 350°C/662°F verdampfen. Einige dieser Verdampfer können auf höhere Temperaturen aufgerüstet werden.These evaporators can only evaporate materials with a boiling point <350 ° C / 662 ° F. Some of these evaporators can be upgraded to higher temperatures.

Neu auf dem Markt sind Verdampfer, genannt „elektronischer Nagel” (Enail Vaporizer), die eine Hitze von bis zu 704,4°C/1300°F erzeugen.New on the market are Evaporators, called "Enamel Vaporizers", which generate heat of up to 704.4 ° C / 1300 ° F.

Diese Enail Vaporizer werden von der Firma Yocantech.com (Shenzhen City, Guangdong, China), nach der Yocan Nero Technology hergestellt und dienen in der vorliegenden Erfindung als Basis für die Verdampfung von Curcumin. Die Systemkonfiguration besteht aus: Authentic Domeless Yocan Thor Enail Vaporizer, einer Wasserpfeife Hookah (ZOBO) ZB-510 und einem Ventil-Ballon (Storz & Bickel GmbH & Co. KG, Tuttlingen)- These Enail vaporizers are manufactured by Yocantech.com (Shenzhen City, Guangdong, China) according to Yocan Nero Technology and are used in the present invention as the basis for the evaporation of curcumin. The system configuration consists of: Authentic Domeless Yocan Thor Enamel Vaporizer, a Hookah (ZOBO) ZB-510 Hookah and a Valve Balloon (Storz & Bickel GmbH & Co. KG, Tuttlingen) -

Als 95%iges Curcumin-Pulver können alle handelsüblichen Präparate BCM-95 eingesetzt werden.As a 95% curcumin powder all commercially available preparations BCM-95 can be used.

In der vorliegenden Erfindung wird die Verdampfung von Curcumin nach zwei Methoden beschrieben:In the present invention, the evaporation of curcumin is described by two methods:

Direkte VerdampfungDirect evaporation

  • 1. Das Curcumin-Pulver wird in eine konische Tasche, angepasst an die Brennkammer (ø ca.15 mm, Höhe ca. 10 mm), aus Edelstahlgewebe (Maschenweite: ≤ 80 mesh, ≤ 177 μm) oder aus Aktivkohle-Vlies fein verteilt in diese Träger gefüllt und dann der Träger in die Brennkammer gelegt.1. The curcumin powder is finely distributed in a conical pocket, adapted to the combustion chamber (ø approx. 15 mm, height approx. 10 mm), made of stainless steel mesh (mesh size: ≤ 80 mesh, ≤ 177 μm) or activated carbon fleece filled in this carrier and then placed the carrier in the combustion chamber.
  • 2. Die mit Curcumin-Pulver gefüllte Tasche wird in die Brennkammer über das Heizelement gelegt.2. The pouch filled with curcumin powder is placed in the combustion chamber over the heating element.

Verdampfung von Curcumin-WachsEvaporation of curcumin wax

  • 1. Das Curcumin-Pulver wird bei 183°C geschmolzen und das Wachs portioniert.1. The curcumin powder is melted at 183 ° C and the wax portioned.
  • 2. Das Curcumin-Wachs wird in die Brennkammer über das Heizelement gelegt.2. The curcumin wax is placed in the combustion chamber over the heating element.

Das so erzeugte Curcumin-Aerosol wird über die Wasserpfeife eingeatmet. Er kann auch direkt eingeatmet werden nachdem er im Glaskolben des Yocan THOR abgekühlt ist. Wird das erzeugte Curcumin-Aerosol in den Ventil-Ballon geleitet kann er zu einer späteren Zeit eingeatmet werden.The curcumin aerosol thus produced is inhaled via the water pipe. It can also be inhaled directly after it has cooled in the glass bulb of Yocan THOR. If the generated curcumin aerosol is directed into the valve balloon, it can be inhaled at a later time.

Vorteile der vorliegenden Erfindung im Unterschied zu den vorhandenen Curcumin-FormulierungenAdvantages of the present invention unlike the curcumin formulations present

  • 1. Das inhalierte Curcumin geht direkt in die Blutbahnen in pharmakologisch relevanten Dosen.1. The inhaled curcumin goes directly into the bloodstream in pharmacologically relevant doses.
  • 2. Curcumin kann die Blut-Hirn-Schranke überwinden und Amyloid-Plaques binden.2. Curcumin can cross the blood-brain barrier and bind amyloid plaques.
  • 3. Umgehung der geringen Bioverfügbarkeit von Curcumin mit seiner schlechten Absorption im Darm.3. Bypass the low bioavailability of curcumin with its poor absorption in the gut.
  • 4. Vermeidung der Glucuronidierung und Biotransformation in der Leber (First-Pass-Stoffwechsel).4. Prevention of glucuronidation and biotransformation in the liver (first-pass metabolism).
  • 5. Reines, wirkstoffreiches Curcumin-Aerosol.5. Pure, active agent-rich curcumin aerosol.
  • 6. Keine Fremdstoffe wie bei bestehenden Curcumin-Formulierungen: Polysorbat (Tween), Triacetin, Panodan (E472e), Glyzerin, u. a..6. No foreign matter as with existing curcumin formulations: polysorbate (Tween), triacetin, Panodan (E472e), glycerin, and the like. a ..
  • 7. Keine großen Kapseln, die nur 6–10% Curcumin pro Kapsel enthalten und der Hauptteil des Inhaltes aus Fremdstoffen besteht.7. No large capsules that contain only 6-10% curcumin per capsule and the bulk of the contents are foreign substances.
  • 8. Mittels Theranostik kann die Eignung und Wirksamkeit des Curcumin-Aerosols für eine bestimmte Krankheit an einem individuellen Patienten bestimmt werden8. Theranostics can be used to determine the suitability and efficacy of the curcumin aerosol for a particular disease in an individual patient
  • 9. In Chemotherapie-Zentren und in Krankenhäusern kann die Herstellung des Curcumin-Aerosols zentral erfolgen und in Ventil-Ballons gespeichert werden. Dia Ventil-Ballons, mit der entsprechenden Dosis, werden dann an die Patienten verteilt.9. In chemotherapy centers and in hospitals, the production of curcumin aerosol can be done centrally and stored in valve balloons. Dia valve balloons, with the appropriate dose, are then distributed to the patients.

In bisherigen Studien wurde keine Toxizität von Curcumin, selbst nach oralen Dosen von 4 Gramm, festgestellt.In previous studies, no toxicity of curcumin was detected, even after oral doses of 4 grams.

Es bedarf aber Studien um die zulässige maximale Konzentration von Curcumin im Blutplasma festzustellen.However, studies are needed to determine the maximum permissible concentration of curcumin in the blood plasma.

ZITATE ENTHALTEN IN DER BESCHREIBUNG QUOTES INCLUDE IN THE DESCRIPTION

Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Zitierte Nicht-PatentliteraturCited non-patent literature

  • Inhalable Curcumin: Offering the Potential for Translation to Imaging and Treatment of Alzheimer's Disease Authors: McClure, Richard | Yanagisawa, Daijiro | Stec, Donald | Abdollahian, Dave | Koktysh, Dmitry | Xhillari, Dritan | Jaeger, Rudolph | Stanwood, Gregg | Chekmenev, Eduard | Tooyama, Ikuo | Gore, John C. | Pham, Wellington [0011] Inhalable Curcumin: Offering the Potential for Translation and Treatment of Alzheimer's Disease Authors: McClure, Richard | Yanagisawa, Daijiro | Stec, Donald | Abdollahian, Dave | Koktysh, Dmitry | Xhillari, Dritan | Jaeger, Rudolph | Stanwood, Gregg | Chekmenev, Eduard | Tooyama, Ikuo | Gore, John C. | Pham, Wellington [0011]
  • DOI: 10.3233/JAD-140798 Journal: Journal of Alzheimer's Disease, vol. 44, no. 1, 2015 Pages 283–295 [0012] DOI: 10.3233 / JAD-140798 Journal: Journal of Alzheimer's Disease, vol. 44, no. 1, 2015 Pages 283-295 [0012]

Claims (8)

Verwendung des Verfahrens zur Erzeugung von Curcumin-Aerosol aus Curcumin-Pulver mit einem Hochleistungs-Verdampfer wobei das Curcumin-Pulver a) in konischen Taschen, angepasst an die Brennkammer des Hochleistungs-Verdampfers, aus Edelstahlgewebe (Maschenweite: ≤ 80 mesh, ≤ 177 μm) oder aus Aktivkohle-Vlies fein verteilt in diese Träger gefüllt wird und dann der Träger in die Brennkammer gelegt wird (CurQInhal), b) geschmolzen bei 183°C als Wachs in die Brennkammer gelegt wird (CurQInhal).Use of the method for producing curcumin aerosol from curcumin powder with a high performance evaporator wherein the curcumin powder a) in conical pockets, adapted to the combustion chamber of the high-performance evaporator, of stainless steel mesh (mesh size: ≤ 80 mesh, ≤ 177 μm) or of activated carbon fleece finely distributed in these carriers and then the carrier is placed in the combustion chamber ( CurQInhal) b) is melted at 183 ° C as wax is placed in the combustion chamber (CurQInhal). Verwendung des Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass das erzeugte Curcumin-Aerosol aufgrund Anspruch 1 a) über die angeschlossene Wasserpfeife eingeatmet werden kann, b) nachdem es abgekühlt ist, direkt aus dem Glaskolben des Hochleistungs-Verdampfers eingeatmet werden kann. c) In einen Ventil-Ballon geleitet werden kann und zu einer späteren Zeit eingeatmet werden kann.Use of the method according to claim 1, characterized in that the generated curcumin aerosol can be inhaled via claim 1 a) via the connected water pipe, b) after it has cooled, can be inhaled directly from the glass bulb of the high-performance evaporator. c) can be directed into a valve balloon and can be inhaled at a later time. Verwendung des Verfahrens nach Anspruch 1a), dadurch gekennzeichnet, dass dem Curcumin-Aerosol ein Aroma-Aerosol beigemischt werden kann.Use of the method according to claim 1a), characterized in that the curcumin aerosol can be admixed with an aroma aerosol. Verwendung des Verfahrens nach Anspruch 1a), dadurch gekennzeichnet, dass andere Materialien und/oder Formen als Träger des Curcumin-Pulvers eingesetzt werden.Use of the method according to claim 1a), characterized in that other materials and / or forms are used as carriers of the curcumin powder. Verwendung des Verfahrens nach Anspruch 1 und 2c), dadurch gekennzeichnet, dass In Chemotherapie-Zentren und in Krankenhäusern die Herstellung des Curcumin-Aerosols zentral erfolgt, in Ventil-Ballons mit der entsprechenden Dosis gespeichert wird und dann an die Patienten verteilt wird.Use of the method according to claims 1 and 2c), characterized in that in chemotherapy centers and in hospitals, the production of the curcumin aerosol is carried out centrally, stored in valve balloons with the appropriate dose and then distributed to the patients. Verwendung des Verfahrens nach Anspruch 1, dadurch gekennzeichnet, dass die Herstellung und der Vertrieb von portioniertem Curcumin-Wachs zur Verwendung nach Anspruch 1b) unter dem Namen CurQInhal erfolgt.Use of the method according to claim 1, characterized in that the production and distribution of portioned curcumin wax for use according to claim 1b) takes place under the name CurQInhal. Verwendung des Verfahrens nach Anspruch 1 und 4, dadurch gekennzeichnet, dass die Herstellung und der Vertrieb von konischen Taschen, angepasst an die Brennkammern der Hochleistungs-Verdampfer, aus Edelstahlgewebe (Maschenweite: ≤ 80 mesh, ≤ 177 μm) oder aus Aktivkohle-Vlies und gefüllt mit portioniertem Curcumin-Pulver zur Verwendung nach Anspruch 1a) unter dem Namen CurQInhal erfolgt.Use of the method according to claim 1 and 4, characterized in that the production and distribution of conical pockets, adapted to the combustion chambers of the high-performance evaporator, made of stainless steel mesh (mesh size: ≤ 80 mesh, ≤ 177 microns) or from activated carbon fleece and filled with portioned curcumin powder for use according to claim 1a) under the name CurQInhal. Verwendung des Verfahrens nach Anspruch 1, dadurch gekennzeichnet, dass anstelle des Curcumin-Pulvers andere nicht wasserlösliche Feststoffe mit einem Siedepunkt > 400°C/> 752°F eingesetzt werden und der Hochleistungs-Verdampfer diese Temperatur erreicht.Use of the method according to claim 1, characterized in that instead of the curcumin powder other non-water-soluble solids with a boiling point> 400 ° C /> 752 ° F are used and the high-performance evaporator reaches this temperature.
DE102015008823.8A 2015-07-15 2015-07-15 Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol Withdrawn DE102015008823A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102015008823.8A DE102015008823A1 (en) 2015-07-15 2015-07-15 Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102015008823.8A DE102015008823A1 (en) 2015-07-15 2015-07-15 Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol

Publications (1)

Publication Number Publication Date
DE102015008823A1 true DE102015008823A1 (en) 2017-01-19

Family

ID=57630315

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102015008823.8A Withdrawn DE102015008823A1 (en) 2015-07-15 2015-07-15 Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol

Country Status (1)

Country Link
DE (1) DE102015008823A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4137540A1 (en) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk USE OF PREPARATIONS OF CURCUMA PLANTS
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
EP2749552A1 (en) * 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
WO2015079198A1 (en) * 2013-11-26 2015-06-04 Twenty Sixteen (2016) Pharma Limited Pulmonary delivery devices

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4137540A1 (en) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk USE OF PREPARATIONS OF CURCUMA PLANTS
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
EP2749552A1 (en) * 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
WO2015079198A1 (en) * 2013-11-26 2015-06-04 Twenty Sixteen (2016) Pharma Limited Pulmonary delivery devices

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"So wenden Sie Gelbwurz an", abgerufen am 22.06.2016 unter http://www.fid-gesundheitswissen.de *
"Vaping Turmeric", Forumsbeitrag in "Alternative Therapies" abgerufen am 22.06.16 unter http://forums.phoenixrising.me *
Inhalable Curcumin: Offering the Potential for Translation to Imaging and Treatment of Alzheimer's Disease Authors: McClure, Richard | Yanagisawa, Daijiro | Stec, Donald | Abdollahian, Dave | Koktysh, Dmitry | Xhillari, Dritan | Jaeger, Rudolph | Stanwood, Gregg | Chekmenev, Eduard | Tooyama, Ikuo | Gore, John C. | Pham, Wellington
VAPIR No.2 - digitaler portabler Vaporizer, Angebot bei Amazon seit Oktober 2012, abgerufen am 23.06.16 unter https://www.amazon.de/Vapir-No2-digitaler-portabler-Vaporizer *
VAPORMED GmbH: Datenblatt Volcano Medic Vaporization System, 2010, abgerufen am 22. 06. 2016 unter www.menzl.com/filearchive/7a0e4f7d73bed0c8f2abeeac881bedb4.pdf *

Similar Documents

Publication Publication Date Title
US20170136076A1 (en) Therapeutic compositions comprising herbal extracts and essential oils for smoking and vaporization
CN104257752B (en) A kind of medical composition and its use for treating rhinitis
Zahra et al. Oral supplementation of Ocimum basilicum has the potential to improves the locomotory, exploratory, anxiolytic behavior and learning in adult male albino mice
Onischuk et al. Ibuprofen, indomethacin and diclofenac sodium nanoaerosol: Generation, inhalation delivery and biological effects in mice and rats
AT501560A1 (en) USE OF HERB CIGARETTES
US20200268824A1 (en) Crocus sativus inhalation apparatus
Vijian et al. Plant extract loaded sodium alginate nanocomposites for biomedical applications: A review
Lansky et al. Harmal: The genus peganum
Asghar et al. Co-combination of pregabalin and Withania coagulans-extract-loaded topical gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury for neuropathic pain in animal model
Walle et al. Sedative-hypnotic like effect of the essential oil from the leaves of Myrtus communis on mice
DE102015008823A1 (en) Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol
Rani et al. Recent advances in medicinal applications of essential oil
CN109966448A (en) The external application herbal-composition for being used to help muscle arthrosis health, recovering from fatigue and handling pain
Zaringhalam et al. Role of the methanolic extracts of Boswellia serrata and Lavandula angustifolia on apomorphine induced ejaculation in male Wistar rats
WO2021080535A2 (en) Memory booster essential oil mixture
De Sousa Anxiolytic essential oils
US20190133926A1 (en) Burn Pill Pharmaceutical Smoking Cylinder
Tishler et al. Endocannabinoid system: Master of homeostasis, pain control, & so much more
Axe et al. The Chemistry of Essential Oils
WO2017051585A1 (en) Inhaling fragrance, perfume, and food flavoring
HEIDARIAN et al. Evaluation of the Effects of Valeriana of Ficinalis Hydroalcoholic Extract on the Morphology of Cerebral Hippocampus Astrocytes in Rats.
JP7334104B2 (en) Dementia improving and/or preventing agent
CN102688450A (en) Local use antalgic traditional Chinese medicine composition as well as preparation method and application thereof
Strižincová et al. Choline Chloride: Lactic Acid as a Green Solvent for the Extraction of Eugenol, Eugenol Acetate, and β-Caryophyllene of Clove Buds
Sindhoora et al. EVALUATION OF ANTI-ANXIETY ACTIVITY OF LAURUS NOBILIS ESSENTIAL OIL IN MICE

Legal Events

Date Code Title Description
R086 Non-binding declaration of licensing interest
R012 Request for examination validly filed
R016 Response to examination communication
R016 Response to examination communication
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee